 | | Health | November 18, 2016 |
As always, if you come across news, announcements, videos, or podcasts that you think everyone else would benefit from, e-mail me at scott.munro@startupdigestmail.com or tweet @R_Scott_Munro.
Quote of the Week
"The increased costs of prescription drugs are one of the most critical items for American families. The development of high-value prescription drugs has improved the health and wellbeing of millions of Medicare and Medicaid beneficiaries. The continued investment in innovation is critical to unlock the treatments for many diseases such as cancer and Alzheimer's, and help us better manage our chronic conditions like diabetes, heart disease and depression, providing significant benefits to patients across the country.
However, in order to have the maximum impact on these innovations, medications must also be affordable and accessible. In the last several months, we have heard about rapidly increasing prices for Epi-Pen, the rising lockstep cost of insulin medications, and the practice of some companies hiking prices by combining two cheaper products into one, higher-priced drug."
- Andy Slavitt
| Health Startup Digest is curated by: |  | R. Scott Munro - MBA Candidate at the University of Chicago Booth School of Business Contact R. Scott Munro at scott.munro@startupdigestmail.com | Save £400 On TechCrunch Disrupt London Tickets!  Dubbed the “Goldilocks” of the tech scene, TechCrunch Disrupt London on 5-6 December is the place to find the startups and people that are just right for you. It's not too big to be overwhelming and not too small to be confining.
Save a total of £400 when you buy your Early Bird ticket with promo code TECHSTARS@EB. Prices go up to £1,200 on 4 December. Buy your tickets today! | | Andy Sparks - Startup Grind If you ever wanted an introduction to CRISPR (trends, companies and people to watch, etc) then look no further than this piece from Andy Sparks. This is a super good primer on the technology. | | John Comstock - Mobihealth News An update on the character-limit marketing regulations coming out from the FDA. The FDA is going to conduct a new study on how formats like Twitter and Google Ads are being used by pharmaceutical firms within the current regulations, and how they should change those regulations. The results of this study will have some serious impacts on how pharma marketers use the mediums. | | Jonathan Oberlander, Ph.D. - NEJM Another overview of some of the impacts on Obamacare we can expect during a Trump Presidency. Overall, it will be very difficult for him to completely repeal the legislation, given the popularity of certain aspects of it (i.e. coverage for preexisting conditions); however, there will certainly be pull back in other regulations (likely subsidies). | | Andy Slavitt, Acting CMS Administrator, Niall Brennan, CMS Chief Data Officer, Tim Gronniger, CMS Deputy Chief of Staff - CMS blog For those that don't know, CMS has an interactive tool that lets you dig into data on spending for particular drugs in Part B and Part D. They have now updated the tool to include overall Medicaid beneficiaries as well as rebates. This is an amazing tool for transparency and analysis (for example, Medicaid spending increased by an astronomical 25% in 2014, much higher than Part B, Part D, or general health expenditure). | | | You are receiving this email because you believe that the best startup articles and videos are made by active members of the startup community. Startup Digest, © 2009-2016 by Techstars Central LLC. All rights reserved. Startup Digest is a registered trademark of Techstars Central, LLC. Privacy Policy | Terms of Use. | |
| _rgb_600_51.png) |
|
